| Shilpa Odedra, MD | |
|
100 Wellness Way, Milford, DE 19963 | |
| (302) 430-5175 | |
| Not Available |
| Full Name | Shilpa Odedra |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 9 Years |
| Location | 100 Wellness Way, Milford, Delaware |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134502545 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | C1-0012528 (Delaware) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Apogee Medical Group Delaware Inc | 9638312572 | 81 |
News Archive
Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade's worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.
Kansas officials readying a move to managed care in their Medicaid program are getting an earful from a host of sources, including other state leaders who have instituted managed care.
According to Millennium Research Group, the global authority on medical technology market intelligence, the new reimbursement system from the Centers for Medicare & Medicaid Services for end stage renal disease will have a mixed but mostly negative effect on the market for ESRD treatment devices.
GlaxoSmithKline and ChemoCentryx, announced today that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 ('786), to placebo.
› Verified 3 days ago
| Entity Name | Apogee Medical Group Delaware Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326485285 PECOS PAC ID: 9638312572 Enrollment ID: O20130826000448 |
News Archive
Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade's worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.
Kansas officials readying a move to managed care in their Medicaid program are getting an earful from a host of sources, including other state leaders who have instituted managed care.
According to Millennium Research Group, the global authority on medical technology market intelligence, the new reimbursement system from the Centers for Medicare & Medicaid Services for end stage renal disease will have a mixed but mostly negative effect on the market for ESRD treatment devices.
GlaxoSmithKline and ChemoCentryx, announced today that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 ('786), to placebo.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shilpa Odedra, MD 100 Wellness Way, Milford, DE 19963-4364 Ph: (302) 430-5175 | Shilpa Odedra, MD 100 Wellness Way, Milford, DE 19963 Ph: (302) 430-5175 |
News Archive
Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade's worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.
Kansas officials readying a move to managed care in their Medicaid program are getting an earful from a host of sources, including other state leaders who have instituted managed care.
According to Millennium Research Group, the global authority on medical technology market intelligence, the new reimbursement system from the Centers for Medicare & Medicaid Services for end stage renal disease will have a mixed but mostly negative effect on the market for ESRD treatment devices.
GlaxoSmithKline and ChemoCentryx, announced today that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 ('786), to placebo.
› Verified 3 days ago
Antonio L Zarraga, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 Wellness Way Ste 200, Milford, DE 19963 Phone: 302-430-0867 Fax: 302-430-0421 | |
Rabail Qureshi, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 W Liberty Way, Milford, DE 19963 Phone: 302-424-3694 | |
Maryam Munir, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 100 Wellness Way, Milford, DE 19963 Phone: 347-325-0762 | |
Ethan Frederick Keller, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 804 N Dupont Blvd, Milford, DE 19963 Phone: 302-725-3557 | |
Meliseanna Katerina Elizabeth Gibbons, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 Wellness Way Ste 200, Milford, DE 19963 Phone: 302-430-0867 Fax: 302-430-0421 | |
Dr. Vikrant R Agrawal, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Wellness Way, Milford, DE 19963 Phone: 302-430-5175 |